Indication
For the treatment of patients with ROS1-positive, advanced non-small-cell lung cancer (NSCLC) not previously treated with ROS-1 inhibitors.
Medicine details
- Medicine name:
- entrectinib (Rozlytrek)
- SMC ID:
- SMC2294
- Pharmaceutical company
- Roche/GSK
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Publication due date:
- 11 January 2021
- SMC meeting date:
- 01 December 2020
- Patient group submission deadline:
- 05 October 2020